Hepatitis C News and Research

Latest Hepatitis C News and Research

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.

8 Nov 2012

EPO provides notice of intent to issue European Patent Application for Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has provided the Company a notice of intent to issue European Patent Application No. 04 703 672.8 entitled "Method For Removal of Viruses From Blood By Lectin Affinity Hemodialysis."

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

State highlights: N.H. hospital in Hepatitis outbreak must allow access to patient records

A New Hampshire judge says a hospital tied to a hepatitis C outbreak must grant public health officials broad access to patient records. Exeter Hospital had argued it would be violating state and federal law if it provided unfettered access to its records system. But a Merrimack County Superior Court judge on Thursday sided with the state.

3 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, indicate that lower liver-related mortality in African American women was independent of other causes of death.

1 Nov 2012

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Allergies and hygiene: an interview with Sally Bloomfield

Allergies occur when the body overreacts to substances in our environment, such as pollen, dust mites and so forth. What happens is that when we are exposed to these potential threats, the immune system should react, deal with it, and then shut down.

26 Oct 2012

Antiviral therapy cuts progression to cancer in hepatitis

Antiviral therapy may prevent the most common form of liver cancer developing among patients who have hepatitis C-related fibrosis or cirrhosis, report researchers.

25 Oct 2012

Rapid and point-of-care tests accurate, convenient for hepatitis C screening

Rapid and point-of-care screening tests for hepatitis C have a high accuracy and quick turnaround time, suggest results of a systematic review and meta-analysis.

24 Oct 2012

Primary care physicians miss hepatitis vaccine targets

Primary care physicians are failing to meet guidelines for hepatitis A virus and hepatitis B virus vaccination in patients with chronic hepatitis C infection, according to US research.

22 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Hepatitis C rapid and point of care tests highly accurate and reliable

Timely screening and diagnosis is critical to the success of new treatments and ultimately to the survival of hepatitis C patients. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) is the first to show that hepatitis C rapid and point of care tests with a quick turnaround time are highly accurate and reliable as conventional first-line laboratory tests.

16 Oct 2012

Statins could be first preventive treatment for liver cancer

Statins may reduce the risk for hepatocellular carcinoma, show the results of a meta-analysis.

15 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

"Indonesia's government has quietly issued an order to override the patents on seven important medicines used to treat people with HIV and hepatitis B and allow cheap versions to be made by local drug companies," Guardian Health Editor Sarah Boseley reports in her "Global Health Blog."

15 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

EPO provides notice of intent to issue European Patent Application for Aethlon Hemopurifier

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

State highlights: N.H. hospital in Hepatitis outbreak must allow access to patient records

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

Allergies and hygiene: an interview with Sally Bloomfield

Antiviral therapy cuts progression to cancer in hepatitis

Rapid and point-of-care tests accurate, convenient for hepatitis C screening

Primary care physicians miss hepatitis vaccine targets

BioLineRx completes pre-clinical development of BL-8020 for HCV

Hepatitis C rapid and point of care tests highly accurate and reliable

Statins could be first preventive treatment for liver cancer

AAPS recognizes top scientists in pharmaceutical sciences

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in